Natera, Inc.
NTRANasdaq
$271.39
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↑ +82.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$38.4B
Enterprise Value
$38.5B
P/E
—
P/S
15.4
P/B
21.6
EV/EBITDA
—
PEG
—
FCF Yield
0.3%
Dividend Yield
—
Revenue (TTM)
$2.5B
Net Income (TTM)
-$226.3M
Free Cash Flow (TTM)
$104.5M
Gross Margin
—
Operating Margin
-13.0%
Net Margin
-9.0%
ROE
-12.8%
ROIC
-13.8%
Debt / Equity
0.0
Net Cash
-$80.3M
Return 1Y
+89.3%
Company profile
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage.
- CEO
- Stephen Chapman
- Sector
- Services
- Industry
- Healthcare
- Employees
- 3,020
- Headquarters
- Texas
- Website
- natera.com
Management & directors
- Rabinowitz MatthewEXECUTIVE CHAIRMAN
- Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
- Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER
- Chapman Steven LeonardCEO AND PRESIDENT
- Fesko JohnPRESIDENT, CHIEF BUS. OFFICER
- Brophy Michael BurkesCHIEF FINANCIAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
NTRA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$696.6M↑ +38.8%
Diluted EPS-$0.60↑ +20.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $391.0M | $625.5M | $820.2M | $1.1B | $1.7B | $2.3B |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$216.3M | -$468.2M | -$541.0M | -$446.2M | -$222.3M | -$309.9M |
| Net income | -$229.7M | -$471.7M | -$547.8M | -$434.8M | -$190.4M | -$208.2M |
| Diluted EPS | -$2.84 | -$5.21 | -$5.57 | -$3.78 | -$1.53 | -$1.52 |
| Operating cash flow | -$182.5M | -$335.2M | -$431.5M | -$247.0M | $135.7M | $215.3M |
| Free cash flow | -$202.1M | -$376.3M | -$479.2M | -$286.2M | $69.2M | $109.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -55.3% | -74.8% | -66.0% | -41.2% | -13.1% | -13.4% |
| Net margin | -58.8% | -75.4% | -66.8% | -40.2% | -11.2% | -9.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $413.4M | $439.8M | $476.1M | $501.8M | $546.6M | $592.2M | $665.5M | $696.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$43.9M | -$39.3M | -$64.7M | -$79.2M | -$110.4M | -$97.6M | -$22.8M | -$93.5M |
| Net income | -$37.5M | -$31.6M | -$53.8M | -$66.9M | -$100.9M | -$87.5M | $47.3M | -$85.1M |
| Diluted EPS | -$0.30 | -$0.26 | -$0.41 | -$0.50 | -$0.74 | -$0.64 | $0.36 | -$0.60 |
| Operating cash flow | $4.0M | $51.8M | $52.9M | $44.5M | $37.6M | $59.4M | $73.9M | $40.2M |
| Free cash flow | -$7.7M | $35.5M | $34.8M | $22.6M | $11.7M | $37.0M | $37.8M | $18.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -10.6% | -8.9% | -13.6% | -15.8% | -20.2% | -16.5% | -3.4% | -13.4% |
| Net margin | -9.1% | -7.2% | -11.3% | -13.3% | -18.5% | -14.8% | 7.1% | -12.2% |
Company news
Jul 20, 2026
Jul 16, 2026
- 3d agoFinalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfoliofinance.yahoo.com
- 4d agoQ1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocksfinance.yahoo.com
- 4d agoBillionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves.fool.com
Jul 10, 2026
- 10d agoNatera (NTRA) Secures EU Certification, Is The Upside Already Priced In?finance.yahoo.com
- 10d agoNatera (NTRA) Signatera Data Shows Who Benefits From Chemotherapy After CRC Surgeryfinance.yahoo.com
- 10d agoCathie Wood Dumps AMD, Doubles Down on Meta Stockfinance.yahoo.com
- 10d agoNatera (NTRA) Stock Still Looks Expensive After A Very Large Runfinance.yahoo.com
- 10d ago1 Cash-Producing Stock with Exciting Potential and 2 We Brush Offfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Sheena Jonathan | Sale | 450 | $273.05 | $122,871.29 | filing |
| 2026-07-15 | Sheena Jonathan | Sale | 390 | $273.01 | $106,473.43 | filing |
| 2026-07-15 | Sheena Jonathan | Sale | 180 | $274.99 | $49,497.44 | filing |
| 2026-07-15 | Sheena Jonathan | Sale | 170 | $275.26 | $46,794.95 | filing |
| 2026-07-15 | Chapman Rowan E | Sale | 135 | $274.82 | $37,100.70 | filing |
| 2026-07-15 | Sheena Jonathan | Sale | 100 | $273.68 | $27,368.40 | filing |
| 2026-07-15 | Sheena Jonathan | Sale | 90 | $274.26 | $24,683.30 | filing |
| 2026-07-15 | Sheena Jonathan | Sale | 80 | $276.02 | $22,081.20 | filing |
| 2026-07-15 | Sheena Jonathan | Sale | 40 | $276.38 | $11,055.20 | filing |
| 2026-07-13 | Sheena Jonathan | Sale | 800 | $264.29 | $211,435.52 | filing |
| 2026-07-13 | Sheena Jonathan | Sale | 500 | $268.39 | $134,193.50 | filing |
| 2026-07-13 | Sheena Jonathan | Sale | 500 | $266.75 | $133,377.00 | filing |
| 2026-07-13 | Sheena Jonathan | Sale | 500 | $262.72 | $131,358.00 | filing |
| 2026-07-13 | Sheena Jonathan | Sale | 450 | $267.72 | $120,474.72 | filing |
| 2026-07-13 | Sheena Jonathan | Sale | 400 | $265.15 | $106,059.52 | filing |
| 2026-07-06 | Rabinowitz Matthew· EXECUTIVE CHAIRMAN | Sale | 1,000 | $280.00 | $280,000.00 | filing |
| 2026-07-01 | RABINOWITZ DANIEL· SEC. AND CHIEF LEGAL OFFICER | Sale | 3,705 | $268.11 | $993,329.77 | filing |
| 2026-07-01 | Moshkevich Solomon· PRESIDENT, CLINICALDIAGNOSTICS | Sale | 2,600 | $272.99 | $709,774.00 | filing |
| 2026-07-01 | RABINOWITZ DANIEL· SEC. AND CHIEF LEGAL OFFICER | Sale | 2,045 | $277.29 | $567,055.80 | filing |
| 2026-07-01 | RABINOWITZ DANIEL· SEC. AND CHIEF LEGAL OFFICER | Sale | 1,955 | $278.25 | $543,972.89 | filing |
| 2026-07-01 | RABINOWITZ DANIEL· SEC. AND CHIEF LEGAL OFFICER | Sale | 1,932 | $268.99 | $519,694.09 | filing |
| 2026-07-01 | RABINOWITZ DANIEL· SEC. AND CHIEF LEGAL OFFICER | Sale | 1,568 | $266.79 | $418,330.64 | filing |
| 2026-07-01 | RABINOWITZ DANIEL· SEC. AND CHIEF LEGAL OFFICER | Sale | 1,400 | $276.24 | $386,739.50 | filing |
| 2026-07-01 | RABINOWITZ DANIEL· SEC. AND CHIEF LEGAL OFFICER | Sale | 1,357 | $270.96 | $367,698.83 | filing |
| 2026-07-01 | RABINOWITZ DANIEL· SEC. AND CHIEF LEGAL OFFICER | Sale | 1,100 | $275.20 | $302,716.92 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.